Clinical trials: Acute Migraine
Migraine
Greater Occipital Nerve Block With Bupivacaine for Acute Migraine
This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using bupivacaine 0.5% for emergency department patients with acute migraine.
- Trial name
- NCT02665273
- Testing
- Greater occipital nerve block, Bupivacaine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Montefiore Medical Center
Migraine Disorders
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
This is a prospective, randomized, open-label study in subjects with migraine who have completed the Phase 3 studies, COL MIG 301/LAHJ (NCT02439320) or COL MIG-302/LAHK (NCT02605174) or for a subset of lasmiditan-naïve subjects…
- Trial name
- GLADIATOR (NCT02565186)
- Testing
- Lasmiditan
- Where
- 196 sites in United States, Germany and 1 more
- Volunteers
- 2,171 people
- Sponsor
- Eli Lilly and Company
Migraine
Efficacy and Tolerability of Zolmitriptan Nasal Spray
The purpose of this study is to evaluate the effectiveness and tolerability (the ability not to experience ill effects from the study drug) of a zolmitriptan nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2…
- Trial name
- NCT00617747
- Testing
- Zolmitriptan
- Volunteers
- 2,114 people
- Sponsor
- AstraZeneca
Acute Migraine With or Without Aura in Adolescents
A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
To provide long term safety data for rizatriptan in children and adolescents. The primary hypothesis of the study is that rizatriptan is well tolerated in the long term treatment of acute migraine in pediatric patients age 12-17…
- Trial name
- NCT01004263
- Testing
- rizatriptan benzoate
- Volunteers
- 674 people
- Sponsor
- Organon and Co
Migraine
RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine Attacks
This study is a prospective, multi-centre, randomised, double-blind, sham-controlled investigation designed for comparison of two parallel treatment groups: gammaCore (active nVNS treatment) and a Sham device (control treatment)…
- Trial name
- NCT02686034
- Testing
- gammaCore-S
- Where
- 10 sites in Italy
- Volunteers
- 285 people
- Sponsor
- ElectroCore INC
Migraine
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
The purpose of this study is to investigate the efficacy and safety of telcagepant (MK-0974) compared to an approved medication for acute migraine.
- Trial name
- NCT00442936
- Testing
- Telcagepant potassium 150 mg, Telcagepant potassium 300 mg, Zolmitriptan 5 mg
- Volunteers
- 1,380 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Disorders
Transnasal Therapy for Acute Migraine Attack
Migraine is a significant health problem in the United States with 34 million Americans suffering from migraine attacks every year. High-flow oxygen has been successfully used in several clinical studies.
- Trial name
- NCT04129567
- Testing
- Humidified oxygen, Dry oxygen, Humidified air
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Acute Mountain Sickness
Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness
Acute mountain sickness (AMS) is a common condition that can occur when healthy people travel quickly to high altitude. Typical symptoms include headache, nausea, tiredness, dizziness, and poor sleep.
- Trial name
- NCT07653516
- Testing
- Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Migraine Disorders, Migraine, Acute
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications…
- Trial name
- NCT00573170
- Testing
- TREXIMET®, Butalbital-containing Combination Medications (BCM)
- Where
- 107 sites in United States
- Volunteers
- 375 people
- Sponsor
- GlaxoSmithKline
Migraine, Cannabis
Efficacy of Inhaled Cannabis for Acute Migraine Treatment
This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.
- Conditions
- Migraine, Cannabis, THC, CBD
- Trial name
- NCT04360044
- Testing
- THC ~5%, CBD ~12%, THC ~5% and CBD ~12%
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- University of California, San Diego
Migraine, Acute
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)
This Clinical Trial evaluates the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents.
- Trial name
- NCT01001234
- Testing
- rizatriptan
- Volunteers
- 1,382 people
- Sponsor
- Organon and Co
Migraine
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007).
- Trial name
- NCT06680206
- Testing
- Rimegepant, Triptans
- Where
- United States
- Volunteers
- 1,395 people
- Sponsor
- Pfizer
Migraine
AVPI Migraine Study
The study is designed as a multicenter, double-blind, randomized, sham-controlled trial to assess the safety and effectiveness of the Nocira AVPI Device for the acute treatment of migraine.
- Trial name
- NC06 (NCT05537818)
- Testing
- AVPI Device
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Nocira, LLC
Migraine
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
- Trial name
- UBR Prodrome (NCT04492020)
- Testing
- Ubrogepant 100 mg
- Where
- 73 sites in United States
- Volunteers
- 518 people
- Sponsor
- AbbVie
Migraine
A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.
- Trial name
- RELIEF (NCT04152083)
- Testing
- Eptinezumab
- Where
- 57 sites in United States, Georgia
- Volunteers
- 485 people
- Sponsor
- H. Lundbeck A/S
Migraine in Adults
Study of Sumatriptan Naproxen Sodium Succinate Tablets for the Treatment of Acute Migraine Attacks
A multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of sumatriptan naproxen sodium succinate tablets in the treatment of acute migraine attacks.
- Trial name
- NCT04948164
- Testing
- sumatriptan 85mg and naproxen sodium 500mg
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Peking University Third Hospital
Migraine With Aura, Migraine Without Aura
Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
In a real-world population of adults with migraine, the investigators would like to investigate whether 12.5 mg almotriptan is non-inferior to 50 mg ubrogepant in terms of pain freedom at 2 hours after drug intake.
- Trial name
- ATOM (NCT05214001)
- Testing
- Almotriptan 12.5 Mg Oral Tablet, Ubrogepant 50Mg Tab
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Messoud Ashina, MD
Migraine Headache, Oxygen
Oxygen in Migraine Treatment
IIn this study, the investigators planned to investigate effectiveness of supplemental oxygen in patients (18-65 years) who were diagnosed as headache related to migraine without aura in the emergency department (ED).
- Trial name
- NCT05780671
- Testing
- oxygen
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people
- Sponsor
- Ankara Ataturk Sanatorium Training and Research Hospital
Acute Migraine
A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.
- Trial name
- NCT04153409
- Testing
- LAT8881
- Where
- 3 sites in Australia
- Volunteers
- 21 people
- Sponsor
- Lateral Pharma Pty Ltd